Levofloxacin inhalation solution for the treatment of chronicPseudomonas aeruginosainfection among patients with cystic fibrosis

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

(2014) Alan R. Smyth et al.   Journal of Cystic Fibrosis

Sublethal Ciprofloxacin Treatment Leads to Rapid Development of High-Level Ciprofloxacin Resistance during Long-Term Experimental Evolution of Pseudomonas aeruginosa

(2013) Karin Meinike Jørgensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis

(2013) Chris Stockmann et al.   Therapeutic Advances in Respiratory Disease

MP-376 (Aeroquin) for chronicPseudomonas aeruginosainfections

(2012) Doina Azoicai et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones

(2012) Chris Stockmann et al.   PEDIATRIC PULMONOLOGY

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems

(2012) Jeffery T. Zobell et al.   PEDIATRIC PULMONOLOGY

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis withPseudomonas aeruginosa

(2011) David E. Geller et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

(2011) David E. Geller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)

(2011) G.L. Kearns et al.   Journal of Cystic Fibrosis

Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis

(2011) David E. Geller et al.   RESPIRATORY MEDICINE

Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation

(2010) Don B. Sanders et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solutionfor inhalation) treatment of chronic pulmonary infections

(2010) Ruslan Tsivkovskii et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis

(2010) Don B. Sanders et al.   PEDIATRIC PULMONOLOGY

New Aerosol Delivery Devices for Cystic Fibrosis

(2010) Kenneth C Kesser et al.   Respiratory Care

Efficacy of Aerosol MP-376, a Levofloxacin Inhalation Solution, in Models of Mouse Lung Infection Due to Pseudomonas aeruginosa

(2009) M. Sabet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

(2009) P. King et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients

(2009) Paula King et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Aerosol antibiotics: considerations in pharmacological and clinical evaluation

(2008) Michael N Dudley et al.   CURRENT OPINION IN BIOTECHNOLOGY

Airway epithelial cell inflammatory signalling in cystic fibrosis

(2008) Jacky Jacquot et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications

(2008) P.C. Griffith et al.   Journal of Cystic Fibrosis

The science of aerosol delivery in cystic fibrosis

(2008) David E. Geller   PEDIATRIC PULMONOLOGY

Molecular Detection of Multiple Emerging Pathogens in Sputa from Cystic Fibrosis Patients

(2008) Fadi Bittar et al.   PLoS One

Pulmonary versus systemic delivery of levofloxacin

(2007) María José de Jesús Valle et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS